India, June 11 -- Shares of Glenmark Pharmaceuticals Limited are likely to remain in focus after the company announced the launch of Winlevi (clascoterone 10 mg/g cream) across key European markets, ...

Glenmark launches Winlevi, a groundbreaking acne treatment, in key European markets, enhancing its dermatology portfolio and ...

Glenmark Specialty S.A (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., announced the launch of Winlevi (clascoterone 10 mg/g cream) across key markets in Europe. This follows the ...

Cosmo N.V. (SIX: COPN) (XETRA: C43) (“Cosmo”) is pleased to make known that its commercial partner Glenmark Specialty S.A (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., today ...

Glenmark Pharmaceuticals announced that its wholly owned subsidiary Glenmark Specialty S.A (GSSA) has launched Winlevi (clascoterone 10 mg/g cream) across key markets in Europe for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . The proportion of patients with facial acne that reached IGA 0/1 increased from 13.5% to 48.9% after 9 months of ...

Detailed price information for Cosmo Pharmaceuticals NV (CMOPF) from The Globe and Mail including charting and trades.

Please provide your email address to receive an email when new articles are posted on . Five of the 69 clascoterone-treated patients had abnormal cosyntropin stimulation test (CST) results. No ...

A discussion on the benefits of combination drug therapy for adherence. Casey Butrus, PharmD: Arash, I want to focus and transition into some of the newer approvals. I know we talked about some newer ...

(HealthDay)—Clascoterone cream, 1 percent, appears to be safe and effective for the treatment of acne, according to a study published online April 22 in JAMA Dermatology. The researchers found that at ...

The efficacy of clascoterone cream 1% for treating acne vulgaris appears to increase over time after 12 weeks of use and up to 1 year. "Clinicians may consider counseling patients that treatment ...

Hair loss, especially androgenetic alopecia—widely recognised as male or female pattern baldness—brings significant emotional distress. It often begins subtly in one’s 20s or 30s and progresses over ...